Weekly Digest – November 2025 Weekly Digest – November 2025 07 November 2025: BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, demonstrates a median overall survival (OS) of 21.5 months in subtypes of refractory soft tissue sarcomas BioAtla shared new Phase 2 data showing that its AXL-targeting […]
Contact:
info@ciscientists.com
+1-908-212-7484
Optimal Dose
For a subscription, please provide your email id